An evaluation of venetoclax in combination with azacitidine, decitabine, or low-dose cytarabine as therapy for acute myeloid leukemia

References

• Döhner H, Weisdorf DJ, Bloomfield CD. Acute myeloid Leukemia. N Engl J Med. 2015;373(12):1136–1152.
   PubMed Web of Science ®Google Scholar
• Shallis RM, Wang R, Davidoff A, et al. Epidemiology of acute myeloid leukemia: recent progress and enduring challenges. Blood Rev. 2019;36:70–87.
   PubMed Web of Science ®Google Scholar
• Davis JR, Benjamin DJ, Jonas BA. New and emerging therapies for acute myeloid leukaemia. J Investig Med. 2018;66(8):1088–1095.
   PubMed Web of Science ®Google Scholar
• Döhner H, Estey EH, Amadori S, et al. Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the european leukemiaNet. Blood. 2010;115(3):453–474.
   PubMed Web of Science ®Google Scholar
• Jonas BA, Pollyea DA. How we use venetoclax with hypomethylating agents for the treatment of newly diagnosed patients with acute myeloid leukemia. Leukemia. 2019;33(12):2795–2804.
   PubMed Web of Science ®Google Scholar
• Wei AH, Strickland SA Jr., Hou JZ, et al., Venetoclax combined with low-dose cytarabine for previously untreated patients with acute myeloid leukemia: results from a phase Ib/II study. J Clin Oncol. 37(15): 1277–1284. 2019.
   PubMed Web of Science ®Google Scholar
• Dinardo CD, Jonas BA, Pullarkat V, et al., Azacitidine and venetoclax in previously untreated acute myeloid leukemia. N Engl J Med. 383(7): 617–629. 2020.
   PubMed Web of Science ®Google Scholar
• Latagliata R, Bongarzoni V, Carmosino I, et al. Acute myelogenous leukemia in elderly patients not eligible for intensive chemotherapy: the dark side of the moon. Ann Oncol. 2006;17(2):281–285.
   PubMed Web of Science ®Google Scholar
• Lagadinou ED, Sach A, Callahan K, et al. BCL-2 inhibition targets oxidative phosphorylation and selectively eradicates quiescent human leukemia stem cells. Cell Stem Cell. 2013;12(3):329–341.
   PubMed Web of Science ®Google Scholar
• Chao DT, Korsmeyer SJBCL. 2 family: regulators of cell death. Annu Rev Immunol. 1998;16(1):395–419.
   PubMedGoogle Scholar
• Pan R, Hogdal LJ, Benito JM, et al. Selective BCL-2 inhibition by ABT-199 causes on-target cell death in acute myeloid leukemia. Cancer Discov. 2014;4(3):362–375.
   PubMed Web of Science ®Google Scholar
• Chan SM, Thomas D, Corces-Zimmerman MR, et al. Isocitrate dehydrogenase 1 and 2 mutations induce BCL-2 dependence in acute myeloid leukemia. Nat Med. 2015;21(2):178–184.
   PubMed Web of Science ®Google Scholar
• Bogenberger JM, Kornblau SM, Pierceall WE, et al. BCL-2 family proteins as 5-Azacytidine-sensitizing targets and determinants of response in myeloid malignancies. Leukemia. 2014;28(8):1657–1665.
   PubMed Web of Science ®Google Scholar
• AbbVie Inc. VENCLEXTA (venetoclax) [package insert]. U.S. Food and Drug Administration website. [cited 2021 Jan 4]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/208573s009lbl.pdf.
   Google Scholar
• Dinardo CD, Pratz K, Pullarkat V, et al., Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia. Blood. 133(1): 7–17. 2019.
   PubMed Web of Science ®Google Scholar
• Juliusson G, Antunovic P, Derolf A, et al. Age and acute myeloid leukemia: real world data on decision to treat and outcomes from the Swedish Acute Leukemia Registry. Blood. 2009;113(18):4179–4187.
   PubMed Web of Science ®Google Scholar
• Appelbaum FR, Gundacker H, Head DR, et al. Age and acute myeloid leukemia. Blood. 2006;107(9):3481–3485.
   PubMed Web of Science ®Google Scholar
• Ferrara F, Barosi G, Venditti A, et al. Consensus-based definition of unfitness to intensive and non-intensive chemotherapy in acute myeloid leukemia: a project of SIE, SIES and GITMO group on a new tool for therapy decision making. Leukemia. 2013;27(5):997–999.
   PubMed Web of Science ®Google Scholar
• Ferrara F. Venetoclax plus hypomethylating agents or low-dose cytarabine in acute myeloid leukemia: all that glitters is gold? Blood Cancer J. 2020;10(1):10.
   PubMed Web of Science ®Google Scholar
• Ma E, Bonthapally V, Chawla A, et al. An evaluation of treatment patterns and outcomes in elderly patients newly diagnosed with acute myeloid leukemia: a retrospective analysis of electronic medical records from US community oncology practices. Clin Lymphoma Myeloma Leuk. 2016;16(11):625–636.e623.
   PubMed Web of Science ®Google Scholar
• Cortes JE, Heidel FH, Heuser M, et al. A phase 2 randomized study of low dose ara-C with or without Glasdegib (PF-04449913) in untreated patients with acute myeloid leukemia or high-risk myelodysplastic syndrome. Blood. 2016;128(22):99.
   Web of Science ®Google Scholar
• Amadori S, Suciu S, Selleslag D, et al. Gemtuzumab ozogamicin versus best supportive care in older patients with newly diagnosed acute myeloid leukemia unsuitable for intensive chemotherapy: results of the randomized phase III EORTC-GIMEMA AML-19 Trial. J Clin Oncol. 2016;34(9):972–979.
   PubMed Web of Science ®Google Scholar
• Strati P, Kantarjian H, Ravandi F, et al. Phase I/II trial of the combination of midostaurin (PKC412) and 5-azacytidine for patients with acute myeloid leukemia and myelodysplastic syndrome. Am J Hematol. 2015;90(4):276–281.
   PubMed Web of Science ®Google Scholar
• Ravandi F, Alattar ML, Grunwald MR, et al. Phase 2 study of azacytidine plus sorafenib in patients with acute myeloid leukemia and FLT-3 internal tandem duplication mutation. Blood. 2013;121(23):4655–4662.
   PubMed Web of Science ®Google Scholar
• Perl AE, Martinelli G, Cortes JE, et al. Gilteritinib or chemotherapy for relapsed or refractory FLT3-mutated AML. N Engl J Med. 2019;381(18):1728–1740.
   PubMed Web of Science ®Google Scholar
• Stein EM, Dinardo CD, Pollyea DA, et al. Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia. Blood. 2017;130(6):722–731.
   PubMed Web of Science ®Google Scholar
• Dinardo CD, Stein EM, De Botton S, et al. Durable remissions with ivosidenib in IDH1-mutated relapsed or refractory AML. N Engl J Med. 2018;378(25):2386–2398.
   PubMed Web of Science ®Google Scholar
• Sallman DA, Asch AS, Kambhampati S, et al. Abstract 330. The first-in-class anti-CD47 antibody magrolimab combined with azacitidine is well-tolerated and effective in AML patients: phase 1b results. Am Soc Hematol. 2020;136:5–8.
   Google Scholar
• Sallman DA, Dezern AE, Garcia-Manero G, et al. Phase 2 results of APR-246 and Azacitidine (AZA) in Patients with TP53 mutant Myelodysplastic Syndromes (MDS) and Oligoblastic Acute Myeloid Leukemia (AML). Blood. 2019;134(Supplement_1):676.
   Web of Science ®Google Scholar
• Ades L, Watts JM, Radinoff A, et al. Phase II study of pevonedistat (P) + azacitidine (A) versus A in patients (pts) with higher-risk myelodysplastic syndromes (MDS)/chronic myelomonocytic leukemia (CMML), or low-blast acute myelogenous leukemia (LB AML) (NCT02610777). J clin oncol. 2020;38(15_suppl):7506.
   Web of Science ®Google Scholar
• Konopleva M, Letai ABCL. 2 inhibition in AML: an unexpected bonus? Blood. 2018;132(10):1007–1012.
   PubMed Web of Science ®Google Scholar
• Bensi L, Longo R, Vecchi A, et al. Bcl-2 oncoprotein expression in acute myeloid leukemia. Haematologica. 1995;80(2):98–102.
   PubMed Web of Science ®Google Scholar
• Tsao T, Shi Y, Kornblau S, et al. Concomitant inhibition of DNA methyltransferase and BCL-2 protein function synergistically induce mitochondrial apoptosis in acute myelogenous leukemia cells. Ann Hematol. 2012;91(12):1861–1870.
   PubMed Web of Science ®Google Scholar
• Jones CL, Stevens BM, D’alessandro A, et al. Inhibition of amino acid metabolism selectively targets human leukemia stem cells. Cancer Cell. 2018;34(5):724–740.e724.
   PubMed Web of Science ®Google Scholar
• Pollyea DA, Stevens BM, Jones CL, et al. Venetoclax with azacitidine disrupts energy metabolism and targets leukemia stem cells in patients with acute myeloid leukemia. Nat Med. 2018;24(12):1859–1866.
   PubMed Web of Science ®Google Scholar
• Oltersdorf T, Elmore SW, Shoemaker AR, et al. An inhibitor of Bcl-2 family proteins induces regression of solid tumours. Nature. 2005;435(7042):677–681.
   PubMed Web of Science ®Google Scholar
• Debrincat MA, Pleines I, Lebois M, et al. BCL-2 is dispensable for thrombopoiesis and platelet survival. Cell Death Dis. 2015;6(4):e1721–e1721.
   PubMedGoogle Scholar
• Souers AJ, Leverson JD, Boghaert ER, et al. ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets. Nat Med. 2013;19(2):202–208.
   PubMed Web of Science ®Google Scholar
• Salem AH, Agarwal SK, Dunbar M, et al. Effect of low- and high-fat meals on the pharmacokinetics of venetoclax, a selective first-in-class BCL-2 inhibitor. J Clin Pharmacol. 2016;56(11):1355–1361.
   PubMed Web of Science ®Google Scholar
• Liu H, Michmerhuizen MJ, Lao Y, et al. Metabolism and disposition of a novel B-cell lymphoma-2 inhibitor venetoclax in humans and characterization of its unusual metabolites. Drug Metab Dispos. 2017;45(3):294–305.
   PubMed Web of Science ®Google Scholar
• Agarwal SK, Dinardo CD, Potluri J, et al. Management of venetoclax-posaconazole interaction in acute myeloid leukemia patients: evaluation of dose adjustments. Clin Ther. 2017;39(2):359–367.
   PubMed Web of Science ®Google Scholar
• Konopleva M, Pollyea DA, Potluri J, et al. Efficacy and biological correlates of response in a phase ii study of venetoclax monotherapy in patients with acute myelogenous leukemia. Cancer Discov. 2016;6(10):1106–1117.
   PubMed Web of Science ®Google Scholar
• Dinardo CD, Pratz KW, Letai A, et al. Safety and preliminary efficacy of venetoclax with decitabine or azacitidine in elderly patients with previously untreated acute myeloid leukaemia: a non-randomised, open-label, phase 1b study. Lancet Oncol. 2018;19(2):216–228.
   PubMed Web of Science ®Google Scholar
• Pollyea DA, Pratz K, Letai A, et al. Venetoclax with azacitidine or decitabine in patients with newly diagnosed acute myeloid leukemia: long term follow-up from a phase 1b study. Am J Hematol. 2020. 10.1002/ajh.26039.
   Web of Science ®Google Scholar
• Wei AH, Montesinos P, Ivanov V, et al., Venetoclax plus LDAC for newly diagnosed AML ineligible for intensive chemotherapy: a phase 3 randomized placebo-controlled trial. Blood. 135(24): 2137–2145. 2020.
   PubMed Web of Science ®Google Scholar
• Pollyea DA, Stahl M, Talati C, et al. Characteristics and outcomes of newly diagnosed acute myeloid leukemia patients receiving venetoclax combinations vs other therapies: results from the AML real world evidence (ARC) Initiative. Blood. 2020;136(Supplement 1):26–28.
   Google Scholar
• Donnellan W, Xu T, Ma E, et al. Use of venetoclax (VEN) and Hypomethylating Agents (HMA) in Newly Diagnosed Acute Myeloid Leukemia (AML) in the United States (US) - Real World (RW) response, treatment duration, dose and schedule moDIfications. Blood. 2020;136(Supplement 1):11–12.
   PubMedGoogle Scholar
• Wolach O, Levi I, Canaani J, et al. First results from a nationwide prospective non-interventional study of venetoclax-based 1st line therapies in patients with Acute Myeloid Leukemia (AML) - revive study. Blood. 2020;136(Supplement 1):27–28.
   Google Scholar
• [cited 2021 Jan 4]. Available from: https://www.ema.europa.eu/en/medicines/human/EPAR/azacitidine-celgene. Accessed 2021 Jan 4.
   Google Scholar
• [cited 2021 Jan 4]. Available from: https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu306370.
   Google Scholar
• [cited 2021 Jan 4]. Available from: https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu3161617.
   Google Scholar
• Administration AGDOHTG. [cited 2021 Jan 4]. Available from: AustralianPublicAssessmentReportforVenetoclaxhttps:wwwtgagovausitesdefaultfilesausparvenetoclax200924docx.
   Google Scholar
• Stone RM, Deangelo DJ, Letai AG, et al. Maximal Tolerated Dose of the BCL-2 Inhibitor Venetoclax in Combination with Daunorubicin/Cytarabine Induction in Previously Untreated Adults with Acute Myeloid Leukemia (AML. Blood. 2020;136(Supplement 1):40–41.
   Google Scholar
• Dinardo CD, Maiti A, Rausch CR, et al. 10-day decitabine with venetoclax for newly diagnosed intensive chemotherapy ineligible, and relapsed or refractory acute myeloid leukaemia: a single-centre, phase 2 trial. Lancet Haematol. 2020;7(10):e724–e736.
   PubMed Web of Science ®Google Scholar
• Lachowiez C, Konopleva M, Kadia TM, et al. Interim analysis of the phase 1b/2 study of the BCL-2 inhibitor venetoclax in combination with standard intensive AML induction/consolidation therapy with FLAG-IDA in patients with newly diagnosed or relapsed/refractory AML. Blood. 2020;136(Supplement 1):18–20.
   Google Scholar
• Daver N, Wei AH, Pollyea DA, et al. New directions for emerging therapies in acute myeloid leukemia: the next chapter. Blood Cancer J. 2020;10(10):107.
   PubMed Web of Science ®Google Scholar
• Zeidan AM, Esteve J, Giagounidis A, et al. The STIMULUS program: clinical trials evaluating sabatolimab (MBG453) combination therapy in patients (pts) with higher-risk myelodysplastic syndromes (HR-MDS) or acute myeloid leukemia (AML. Blood. 2020;136(Supplement 1):45–46.
   Google Scholar
• Short NJ, Sedarati F, Zhao D, et al. A randomized phase 2 study of pevonedistat, venetoclax, and azacitidine versus venetoclax plus azacitidine in adults with newly diagnosed acute myeloid leukemia (AML) who are unfit for intensive chemotherapy. Blood. 2020;136(Supplement 1):34–35.
   Google Scholar
• Daver N, Sweet KL, Montesinos P, et al. A phase 1b/2 study of IMGN632, a CD123-targeting antibody-drug conjugate (ADC), as monotherapy or in combination with venetoclax and/or azacitidine for patients with CD123-positive acute myeloid leukemia. Blood. 2020;136(Supplement 1):50–51.
   PubMed Web of Science ®Google Scholar
• Tm BG K, Pemmaraju N, Daver N, et al. Abstract 25. phase ii study of venetoclax added to cladribine + low dose araC (LDAC) alternating with 5-azacytidine demonstrates high rates of minimal residual disease (MRD) negative complete remissions (CR) and excellent tolerability in older patients with newly diagnosed acute myeloid leukemia (AML)Blood 2020; 136 (Supplement 1):17–19.
   Google Scholar
• Lachowiez CA, Borthakur G, Loghavi S, et al. Phase Ib/II study of the IDH1-mutant inhibitor ivosidenib with the BCL2 inhibitor venetoclax ± azacitidine in IDH1-mutated hematologic malignancies. J clin oncol. 2020;38(15_suppl):7500.
   Web of Science ®Google Scholar
• Maiti A, Rausch CR, Cortes JE, et al. Outcomes of relapsed or refractory acute myeloid leukemia after frontline hypomethylating agent and venetoclax regimens. Haematologica. 2020. 10.3324/haematol.2020.252569.
   Web of Science ®Google Scholar
• Taksin AL, Legrand O, Raffoux E, et al. High efficacy and safety profile of fractionated doses of Mylotarg as induction therapy in patients with relapsed acute myeloblastic leukemia: a prospective study of the alfa group. Leukemia. 2007;21(1):66–71.
   PubMed Web of Science ®Google Scholar
• Othman TA, Zhang J, Mei M, et al. Retreatment with venetoclax and hypomethylating agents among AML patients who have relapsed after initial response and subsequent interruption of therapy. Leuk Lymphoma. 2020;61(14):3532–3533.
   PubMed Web of Science ®Google Scholar
• Ritchie EK, Roboz GJ. Levels of care: defining best supportive care in elderly patients with acute myeloid leukemia. Curr Hematol Malig Rep. 2010;5(2):95–100.
   PubMed Web of Science ®Google Scholar
• Sekeres MA, Gerds AT. The graceful exit or reluctant demise of the older adult with acute myeloid leukemia. Cancer. 2015;121(16):2678–2680.
   PubMed Web of Science ®Google Scholar
• Pan R, Ruvolo V, Mu H, et al. Synthetic lethality of combined bcl-2 inhibition and p53 activation in aml: mechanisms and superior antileukemic efficacy. Cancer Cell. 2017;32(6):748–760.e746.
   PubMed Web of Science ®Google Scholar
• Pei S, Pollyea DA, Gustafson A, et al. Monocytic subclones confer resistance to venetoclax-based therapy in patients with acute myeloid leukemia. Cancer Discov. 2020;10(4):536–551.
   PubMed Web of Science ®Google Scholar
• Tahir SK, Smith ML, Hessler P, et al. Potential mechanisms of resistance to venetoclax and strategies to circumvent it. BMC Cancer. 2017;17(1):399.
   PubMed Web of Science ®Google Scholar
• Jones CL, Stevens BM, Pollyea DA, et al. Nicotinamide metabolism mediates resistance to venetoclax in relapsed acute myeloid leukemia stem cells. Cell Stem Cell. 2020;27(5):748–764.e744.
   PubMed Web of Science ®Google Scholar
• Dinardo CD, Tiong IS, Quaglieri A, et al. Molecular patterns of response and treatment failure after frontline venetoclax combinations in older patients with AML. Blood. 2020;135(11):791–803.
   PubMed Web of Science ®Google Scholar
• Saliba AN, John AJ, Kaufmann SH. Resistance to venetoclax and hypomethylating agents in acute myeloid leukemia. Cancer Drug Resist. 2021;4:125–142.
   PubMedGoogle Scholar
• Sandhu KS, Dadwal S, Yang D, et al. Outcome of allogeneic hematopoietic cell transplantation after venetoclax and hypomethylating agent therapy for acute myelogenous leukemia. Biol Blood Marrow Transplant. 2020;26(12):e322–e327.
   PubMed Web of Science ®Google Scholar
• Mei M, Aldoss I, Marcucci G, et al. Hypomethylating agents in combination with venetoclax for acute myeloid leukemia: update on clinical trial data and practical considerations for use. Am J Hematol. 2019;94(3):358–362.
   PubMed Web of Science ®Google Scholar
• Dinardo CD, Wei AH. How I treat acute myeloid leukemia in the era of new drugs. Blood. 2020;135(2):85–96.
   PubMed Web of Science ®Google Scholar
• https://www.nccn.org/professionals/physician_gls/pdf/aml.pdf Accessed 2021 Jan 4.
   Google Scholar
• Pratz KW, Dinardo CD, Selleslag D, et al. Cytopenia management in patients with newly diagnosed acute myeloid leukemia treated with venetoclax plus azacitidine in the VIALE-A study. Blood. 2020;136(Supplement 1):51–53.
   Google Scholar
• VIDAZA (azacitidine) [package insert]. U.S. food and drug administration website. [cited 2021 Jan 4]. Available from: https://www.accessdatafdagov/drugsatfda_docs/label/2008/050794s011lblpdf.
   Google Scholar
• DACOGEN (decitabine) [package insert] U.S. food and drug administration website. [cited 2021 Jan 4]. Available from: https://www.accessdatafdagov/drugsatfda_docs/label/2010/021790s006lblpdf].
   Google Scholar
• [cited 2021 Jan 4]. Available from: https://www.leukemia-net.org/content/home/index_eng.html.
   Google Scholar